Lifog

Latanoprost, the active ingredient in Lifog, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It lowers intra‑ocular pressure and is indicated for the treatment of open‑angle glaucoma and ocular hypertension in adult patients. The medication works by enhancing fluid outflow from the eye, helping to preserve visual function.

GNH USA supplies Lifog as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures consistent quality and regulatory compliance across EU and global markets.

Latanoprost is a prostaglandin analog used to manage ocular pressure in glaucoma and related conditions. - Open-angle glaucoma: reduces intra‑ocular pressure to slow disease progression. - Ocular hypertension: lowers eye pressure to prevent development of glaucoma. - Pseudoexfoliative glaucoma: improves fluid outflow to control intra‑ocular pressure.

Latanoprost may cause ocular and systemic adverse reactions; the frequency varies among patients.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Increased eyelash growth: longer, thicker lashes. - Iris pigmentation: gradual darkening of eye color.

Serious or Rare Side Effects: - Severe ocular inflammation: uveitis or iritis requiring treatment. - Paradoxical intra‑ocular pressure increase: unexpected rise in pressure. - Macular edema: fluid accumulation affecting central vision.

When prescribing Latanoprost, clinicians should consider several precautionary measures to ensure patient safety. - Pregnancy: safety not established; avoid unless benefit outweighs risk. - Breastfeeding: unknown excretion; consider potential risk to infant. - Ocular surgery: postpone elective procedures for at least four weeks after discontinuation. - Intra‑ocular pressure monitoring: assess response regularly after initiation. - Active ocular infection: do not use until infection resolved. - Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost can interact with other ophthalmic or systemic agents; awareness of these interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Concomitant use with other intra‑ocular pressure‑lowering agents may cause excessive hypotension. - Combination with non‑steroidal anti‑inflammatory eye drops can increase ocular irritation. - Simultaneous systemic carbonic anhydrase inhibitors may lead to overly low eye pressure.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: monitor for additive pressure reduction. - Alpha‑agonist eye drops: observe for combined hypotensive effect.